EDSA News and Press, Edesa Biotech Inc. From 09/30/22

Edesa Biotech ( NASDAQ: EDSA ) on Friday announced final results from a phase 2 study that showed its experimental monoclonal antibody candidate EB05 in combination with standard of care (SOC) reduced the risk of death in hospitalized COVID-19 patients by 84%, an improvement o...

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significant EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo Clinical Study Report submitted to FDA TORONTO, ON / ACCESSWIRE / September 30, 2022 / Edes...

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investm...

Edesa Biotech, Inc. ( NASDAQ: EDSA ), a Canadian company focused on inflammatory and immune-related diseases, added ~7% in the pre-market trading Wednesday after the biotech announced it reached the full enrollment of its Phase 2b clinical study for anti-allergic treatment...

Primary Endpoint To Be Reached Within 30 Days, With Topline Data Available by End of Year Company Evaluating Partnership and Out-Licensing Opportunities Outside North America for Its First-in-Class, Anti-Inflammatory Drug Candidate TORONTO, ON / ACCESSWIRE / September 7, 2022 / E...

Edesa Biotech press release ( NASDAQ: EDSA ): Q3 GAAP EPS of -$0.37 beats by $0.06 . At June 30, 2022, Edesa had cash and cash equivalents of $12.81 million and working capital of $9.52 million. For further details see: Edesa Biotech GAAP EPS of -$0.37 beats ...

Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inf...

TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being he...

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development S...

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Pha...